Related references
Note: Only part of the references are listed.Efficacy and safety of methotrexate, omalizumab and dupilumab for bullous pemphigoid in patients resistant or contraindicated to oral steroids. A monocentric real-life study
M. Velin et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2022)
Clinical Effectiveness and Safety of Initial Combination Therapy with Corticosteroids and Rituximab in Bullous Pemphigoid: A Retrospective Cohort Study
Yun-Ju Tsai et al.
AMERICAN JOURNAL OF CLINICAL DERMATOLOGY (2022)
Omalizumab for the Treatment of Bullous Pemphigoid: A Systematic Review of Efficacy and Safety
Kathleen D'Aguanno et al.
JOURNAL OF CUTANEOUS MEDICINE AND SURGERY (2022)
Treatment of bullous pemphigoid with dupilumab: Dupilumab exerts its effect by primarily suppressing T-helper 2 cytokines
Saori Takamura et al.
JOURNAL OF DERMATOLOGY (2022)
Dupilumab combined with low-dose systemic steroid therapy improves efficacy and safety for bullous pemphigoid
Jin Yang et al.
DERMATOLOGIC THERAPY (2022)
Rituximab, Omalizumab, and Dupilumab Treatment Outcomes in Bullous Pemphigoid: A Systematic Review
Peng Cao et al.
FRONTIERS IN IMMUNOLOGY (2022)
International validation of the Bullous Pemphigoid Disease Area Index severity score and calculation of cut-off values for defining mild, moderate and severe types of bullous pemphigoid
W. Masmoudi et al.
BRITISH JOURNAL OF DERMATOLOGY (2021)
Treatment of Bullous Pemphigoid in People Aged 80 Years and Older: A Systematic Review of the Literature
Meital Oren-Shabtai et al.
DRUGS & AGING (2021)
The emerging role of dupilumab in dermatological indications
Maddalena Napolitano et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2021)
Efficacy and Safety of Dupilumab in Moderate-to-Severe Bullous Pemphigoid
Yihua Zhang et al.
FRONTIERS IN IMMUNOLOGY (2021)
Evaluation and Comparison of Clinical and Laboratory Characterstics of Patients With IgA Epidermolysis Bullosa Acquisita, Linear IgA Bullous Dermatosis, and IgG Epidermolysis Bullosa Acquisita
Mareike Becker et al.
JAMA DERMATOLOGY (2021)
Differential effects of short- and long-term treatment with mepolizumab on eosinophil kinetics in blood and sputum in eosinophilic asthma
Marwan Hassani et al.
ISCIENCE (2021)
Mepolizumab failed to affect bullous pemphigoid: A randomized, placebo-controlled, double-blind phase 2 pilot study
Dagmar Simon et al.
ALLERGY (2020)
Rituximab in autoimmune pemphigoid diseases: Indications, optimized regimens, and practice gaps
Renee M. Thomas et al.
CLINICS IN DERMATOLOGY (2020)
Clinical outcome and safety of rituximab therapy for pemphigoid diseases
Napatra Tovanabutra et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2020)
Treatment with anti-neonatal Fc receptor (FcRn) antibody ameliorates experimental epidermolysis bullosa acquisita in mice
Anika Kasprick et al.
BRITISH JOURNAL OF PHARMACOLOGY (2020)
A Review Comparing International Guidelines for the Management of Bullous Pemphigoid, Pemphigoid Gestationis, Mucous Membrane Pemphigoid, and Epidermolysis Bullosa Acquisita
Payal M. Patel et al.
AMERICAN JOURNAL OF CLINICAL DERMATOLOGY (2020)
Dupilumab as a novel therapy for bullous pemphigoid: A multicenter case series
Rana Abdat et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2020)
Association Between Medication Use and Bullous Pemphigoid A Systematic Review and Meta-analysis
Sian-De Liu et al.
JAMA DERMATOLOGY (2020)
Rituximab therapy in patients with bullous pemphigoid: A retrospective study of 20 patients
Maxim Polansky et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2019)
The Ethanol Extract of Holotrichia diomphalia Larvae, Containing Fatty acids and Amino acids, Exerts Anti-Asthmatic Effects through Inhibition of the GATA-3/Th2 Signaling Pathway in Asthmatic Mice
Jung-Hee Hong et al.
MOLECULES (2019)
RoB 2: a revised tool for assessing risk of bias in randomised trials
Jonathan A. C. Sterne et al.
BMJ-BRITISH MEDICAL JOURNAL (2019)
Systematic Review of Safety and Efficacy of Rituximab in Treating Immune-Mediated Disorders
Celine Kaegi et al.
FRONTIERS IN IMMUNOLOGY (2019)
Rituximab and Omalizumab for the Treatment of Bullous Pemphigoid: A Systematic Review of the Literature
Noa Kremer et al.
AMERICAN JOURNAL OF CLINICAL DERMATOLOGY (2019)
Effectiveness and Safety of Rituximab in Recalcitrant Pemphigoid Diseases
Aniek Lamberts et al.
FRONTIERS IN IMMUNOLOGY (2018)
Anti-Type VII Collagen Antibodies Are Identified in a Subpopulation of Bullous Pemphigoid Patients With Relapse
Delphine Giusti et al.
FRONTIERS IN IMMUNOLOGY (2018)
A Distinct Clinicopathological Presentation of Cutaneous Dermatophytosis Mimicking Autoimmune Blistering Disorder
Jignaben Krunal Padhiyar et al.
INDIAN JOURNAL OF DERMATOLOGY (2018)
The Role of Eosinophils in Bullous Pemphigoid: A Developing Model of Eosinophil Pathogenicity in Mucocutaneous Disease
Kyle T. Amber et al.
FRONTIERS IN MEDICINE (2018)
Bullous Pemphigoid: A Review of its Diagnosis, Associations and Treatment
Philippe Bernard et al.
AMERICAN JOURNAL OF CLINICAL DERMATOLOGY (2017)
The Reliability, Validity and Responsiveness of Two Disease Scores (BPDAI and ABSIS) for Bullous Pemphigoid: Which One to Use?
Asri Wijayanti et al.
ACTA DERMATO-VENEREOLOGICA (2017)
Rituximab combined with conventional therapy versus conventional therapy alone for the treatment of mucous membrane pemphigoid (MMP)
Alexander Maley et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2016)
ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions
Jonathan A. C. Sterne et al.
BMJ-BRITISH MEDICAL JOURNAL (2016)
ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions
Jonathan A. C. Sterne et al.
BMJ-BRITISH MEDICAL JOURNAL (2016)
Efficacy of Rituximab for Pemphigus: A Systematic Review and Meta-analysis of Different Regimens
Hsiao-Han Wang et al.
ACTA DERMATO-VENEREOLOGICA (2015)
First-line combination therapy with rituximab and corticosteroids provides a high complete remission rate in moderate-to-severe bullous pemphigoid
Y. T. Cho et al.
BRITISH JOURNAL OF DERMATOLOGY (2015)
Management of bullous pemphigoid: the European Dermatology Forum consensus in collaboration with the European Academy of Dermatology and Venereology
C. Feliciani et al.
BRITISH JOURNAL OF DERMATOLOGY (2015)
Omalizumab therapy for bullous pemphigoid
Kenneth K. Yu et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2014)
Functional Characterization of an IgE-Class Monoclonal Antibody Specific for the Bullous Pemphigoid Autoantigen, BP180
Kelly A. N. Messingham et al.
HYBRIDOMA (2012)
Definitions and outcome measures for bullous pemphigoid: Recommendations by an international panel of experts
Dedee F. Murrell et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2012)
Bullous and mucous membrane pemphigoid show a mixed response to rituximab: experience in seven patients
S. Lourari et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2011)
Prostaglandin D2 reinforces Th2 type inflammatory responses of airways to low-dose antigen through bronchial expression of macrophage-derived chemokine
K Honda et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2003)
Share Paper
